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1 Drug description 
Generic/Brand name:  
Pazopanib, GW786034 (Votrient ®) 
Developer/Company:  
Glaxo Group Limited 
Description:  
Pazopanib is an orally administered antineoplastic agent that targets multi-
ple tyrosine kinase inhibitors (TKIs) which are involved in angiogenesis, 
tumour growth and metastatic progression of cancer [1]. In detail, pazopanib 
inhibits vascular endothelial growth factor receptor (VEGFR), platelet-
derived growth factor receptor (PDGFR) and c-KIT. These receptors can be 
found on the surface of cancer cells and are responsible for growth and 
spread of the tumour. By targeting these receptors, growth and spread of the 
tumour should be reduced [2]. 
Other multi-targeting TKIs targeting VEGFR and PDGFR, such as sunit-
inib and sorafenib, are already approved for the treatment of renal cell car-
cinoma (RCC). 
The recommended daily dose of pazopanib is 800mg administered orally as 
a film-coated tablet at least 1 hour prior or 2 hours after a meal. In the piv-
otal study VEG105192 [3] patients received pazopanib until disease progres-
sion, death, unacceptable toxicity or withdrawal of consent. Pazopanib is 
only approved for adult patients. 
Due to the safety results of pazopanib trials that showed serious liver-related 
adverse events, it is recommended to perform serum liver tests prior to ini-
tiation of pazopanib therapy and regularly thereafter in patients with ad-
vanced or metastatic RCC [2]. 
2 Indication 
Pazopanib (Votrient ®) is indicated as monotherapy for the treatment of 
therapy-naïve patients with advanced renal cell carcinoma or in RCC pa-
tients who have failed prior cytokine-based systemic therapy. 
Pazopanib/Votrient ® 
orally administered; 
targeting multiple TKIs 
– VEGFR, PDGFR, c-Kit 
recommended daily 
dose: 800mg 
liver function test prior 
to therapy strongly 
recommended 
monotherapy, first-line 
and after failed 
cytokine-based therapy 
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3 Current regulatory status 
In June 2010, the European Medicines Agency (EMA) has granted condi-
tional approval of pazopanib (Votrient ®) for the treatment of advanced 
and/or metastatic RCC for the first-line treatment or after initial cytokine-
based therapy has failed. Votrient® was approved under the condition that 
the marketing authorisation holder submits mature OS data of the pivotal 
VEG105192 trial by 2012 and efficacy and safety data of the ongoing head-
to-head COMPARZ [4] trial, comparing pazopanib and sunitinib in RCC 
[2]. The comparator sunitinib was chosen, because its efficacy and safety 
profile was similar to the efficacy and safety profile of pazopanib when both 
were compared to placebo [2, 5]. 
In October 2009, the US Food and Drug Administration (US FDA) ap-
proved pazopanib (Votrient ®) for the same indication as EMA in June 
2010. The American FDA does explicitly not recommend pazopanib for the 
treatment of RCC patients with severe hepatic impairment [6]. 
4 Burden of disease 
In 2007, 1181 patients (men: 705; women: 476) were newly diagnosed with 
kidney cancer and 407 kidney cancer patients (men: 222; women: 185) died 
due to their disease in Austria [7]. 
RCC, a type of kidney cancer, accounts for approximately 90% of all kidney 
cancers [3]. Generally, 5 histological types of carcinoma are differentiated: 
- clear cell (approximately 60%) 
- papillary (7-14%) 
- chromophobe (6-11%) 
- oncocytoma (7-10%) 
- and collecting duct (<1%) [8].  
Associated risk factors are smoking and obesity, as well as genetic abnor-
malities. Median age of RCC diagnosis is between 50-70 years with more 
men than women being affected [9]. 
Risk stratification is important for choosing the most appropriate therapy. 
The most common model to predict short survival is the Memorial Sloan-
Kettering Cancer Centre or informally known as the Motzer criteria 
(MSKCC) which are based on risk-factors or predictors, such as high blood 
levels of lactate dehydrogenase and calcium, anaemia, time of less than a 
year from diagnosis to the need for systemic treatment and low performance 
status (Karnofsky performance status <80%). Depending on the number of 
risk factors three groups can be stratified: a good, intermediate or poor risk-
group [10]. 
06/2010 EMA granted 
conditional marketing 
authorisation 
request for mature OS 
data and head-to-head 
comparison 
10/2009 US FDA 
approval – not for 
patients with severe 
hepatic impairment 
1181 newly diagnosed 
kidney cancer in 2007 
90% of kidney cancers 
are RCCs 
median age at diagnosis 
50-70 years 
risk stratification for the 
choice of therapy (e.g. 
with MSKCC) 
three risk groups: good, 
intermediate and poor 
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The TNM-staging system is used for the clinical staging of RCCs, consider-
ing the size of the tumour, involved lymph nodes and metastasis [11]. In 
contrast to localized tumours with a high probability of cure (stage I/II), 
more advanced forms with either metastases in the regional lymph nodes 
(stage III) or with distant metastases (stage IV) of kidney cancer are linked 
to poor outcomes. Estimated average 5-year survival rate for patients ranges 
from 23% (stage IV) to 64% (stage III) [10]. 
Due to an often asymptomatic course of the disease, about 25% to 30% of 
patients are diagnosed when the tumour has already metastasised [9]. 
Applying these estimates and considering that pazopanib is indicated for the 
treatment of patients with advanced RCC with histological clear cell type 
(study population of the pivotal VEG105192 study [3]), approximately 200 
newly diagnosed patients will be eligible to receive pazopanib treatment in 
Austria every year. 20% to 30% of patients with previously localized tu-
mours relapse one to two years after surgery [10]. 
5 Current treatment 
The standard of care for patients with RCC  is nephrectomy followed by ei-
ther observation or - if possible - the enrolment into clinical trials [10]. For 
patients who relapse after surgical excision of the tumour or who are not eli-
gible for resection in the first place, the choice of therapy depends on differ-
ent factors like tumour stage and histology, absence or presence of metasta-
ses etc. For the first- and second-line treatment of RCC patients, cytokines 
(IL-2 and IFN-α) and targeted agents (like sunitinib malate, sorafenib tosy-
late, temsirolimus, everolimus and bevacizumab) are used [10]. 
Reviews show that the resistance of patients with RCC to cytotoxic therapy, 
radiation or hormone therapy is very high [3]. Therefore, cytokines were, de-
spite their limited clinical efficacy and significant toxicity, the choice of 
therapy until new targeted agents have been developed recently [3, 12]. 
Clinical studies show that response rates to cytotoxic therapy with IFN-α 
and/or IL-2 are generally less than 10% and that consequently, resistance to 
these agents is very high [13]. Thus, new treatment strategies for advanced 
and/or metastatic RCC are needed. Advances in the understanding of RCC 
tumour biology, including the role of VEGF and mTOR pathways, led to the 
clinical development of several targeted agents for the treatment of RCC [3]. 
Currently, there are, besides pazopanib, five targeted agents approved by the 
FDA and the EMA for RCC therapy:  
- sunitinib malate (Sutent®), 
- sorafenib tosylate (Nexavar®), 
- temsirolimus (Torisel®), 
- everolimus (Aftinitor®) 
- and bevcacizumab (Avastin®) in combination with interferon [10]. 
TNM-staging system 
has prognostic relevance 
5-year survival for stage 
III 64% and stage IV 
23% 
25-30% have metastatic 
disease at time of 
diagnosis 
surgical excision is 
primary choice of 
therapy in RCC patients 
low response rate of 
10% and resistance to 
cytotoxic therapy, 
hormone therapy or 
radiation 
since 2006 six new 
targeted agents for the 
treatment of RCC have 
been approved 
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6 Evidence 
Based on a limited literature search 2 trials meeting the pre-defined inclu-
sion criteria for the efficacy section of this horizon scanning report could be 
identified. Sternberg et al. 2010 [3] published the findings and data of a 
multinational and multicenter phase III study evaluating the safety and effi-
cacy of the new TKI pazopanib in the treatment of advanced and/or metas-
tatic RCC in treatment-naïve or cytokine pre-treated patients compared to 
placebo. This study included 435 patients – 233 were treatment naïve and 
202 patients were pre-treated with cytotoxic therapy. The approval of pa-
zopanib in the US in 2009 and in Europe in 2010 was mainly based on these 
results. 
Further, a phase II randomized discontinuation trial (consisting of a lead-in 
phase, followed by 3 options: continuation or discontinuation of therapy or 
randomization; this trial design is described in more detail elsewhere [14]) 
assessing the safety and efficacy in 225 patients was identified. As described 
below, this study consisted of an open-label phase, where all patients were 
treated with pazopanib, followed by a randomized, placebo-controlled phase. 
Only patients with stable disease were per protocol eligible for randomiza-
tion. 
6.1 Efficacy and safety - Phase III studies 
Table 1: Phase III trial – safety and efficacy results 
Reference  Sternberg et al. 2010 [3]; VEG105192 study, NCT00334282 
Sponsor GlaxoSmithKline Pharmaceuticals, Philadelphia, PA 
Country 80 centers in Europe, Asia, South America, North Africa, Australia, New Zealand 
Design Randomized, placebo-controlled, multicenter trial 
Participants characteris-
tics 
435 pts – I(ntervention): 290; C(ontrol): 145; median age: I 59 years (range 2-85) vs C 60 
years (range 25 – 81); men: I 68% vs C 75% 
Treatment-nai¨ve subpopulation: I 155 pts (53%)  vs C 78 pts (54%) 
Cytokine pre-treated subpopulation: I 135 pts (47%) vs C 67 pts ( 46%) 
Treatments I(ntervention): 800mg pazopanib once daily, administered orally, dose modification guide-
lines for AEs were pre-specified 
C(ontrol): placebo matching pazopanib 
Patients who had progressive disease were unblinded and if they had received placebo, they 
were offered to be treated with pazopanib within an open-label study (VEG107769). 48% 
of placebo-arm patients enrolled in that trial 
In-/exclusion criteria Inclusion: 
Pts with advanced and/or metastatic RCC, who had progressed on one prior cytokine-based 
systemic therapy or who are treatment nai¨ve; diagnosis of clear-cell or predominantly 
clear-cell histology; ECOG PS ≤ 1, adequate renal, hepatic, and hematologic function 
Exclusion: 
Pts with CNS metastasis, leptomeningeal lesions, poorly controlled hypertension 
Follow-up Follow-up for overall survival was performed every 3 months after disease progression until 
death or study withdrawal 
Outcomes Primary: progression free survival (PFS) 
Secondary: overall survival (OS), objective response rate (=complete response (CR) and 
partial response (PR)), duration of response, safety, health-related quality of life (HRQL) 
 
1 phase III trial and one 
phase II trial  
two subgroups: 
treatment-nai¨ve and 
cytokine pre-treated 
patients 
randomized 
discontinuation study 
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Key results  
 
Primary outcomes 
Median PFS( I vs. C):  
- Overall study population: HR 0.46; 95% CI, 0.34 to 0.62; p <0.0001 (9.2 vs. 4.2 
months (mths)) 
- Treatment nai¨ve subgroup: HR 0.40; 95% CI, 0.27 to 0.60; p <0.0001 (11.1 vs. 2.8 
mths) 
- Cytokine pre-treated subgroup: HR 0.54; 95% CI, 0.35 to 0.84; p <0.001 (7.4 vs. 
4.2 mths) 
 
Secondary outcomes 
OS: at time of interim analysis the required events for final OS analysis had not yet oc-
curred. Mature data on OS will be reported when available. 
 
Response rate (I vs. C):  
- Overall study population: 30% (95% CI, 25.1 to 35.6) vs. 3% (95% CI, 0.5 to 6.4); 
median duration of response: 58.7 weeks (wks) (95% CI, 52.1 to 68.1) vs. not 
mentioned 
- Treatment nai¨ve subgroup: 32% (95% CI, 24.3 to 38.9) vs. 4% (95%  CI, 0.0 vs. 
8.1) 
- Cytokine pre-treated subgroup: 29% (95% CI, 21.2 to 36.5) vs. 3% (95% CI, 0.0 to 
7.1) 
 
Health-related quality of life (HRQL): 
The mixed-model repeated-measures analyses did not show statistical significant difference 
between pazopanib and placebo treated groups at any assessment time point. 
Adverse effects Most common observed adverse events (AEs):  
diarrhea (I 52% vs C 9%), hypertension (I 40% vs C 10%), hair colour changes (I 38% vs C 
3%), nausea (I 26% vs C 9%), anorexia (I 22% vs C 10%), vomiting (I 21% vs C 8%), hem-
orrhagic events (I 13% vs C 5%), elevations in alanine aminotransferase (ALT) (I 53% vs C 
22%) and elevations in  aspartate aminotransferase (AST) (I 53% vs C 19%). 
Grade 3 and 4 AEs were observed in 33% and 7%, respectively in the pazopanib arm com-
pared to 14% and 6%, respectively in the placebo arm.  
Hypertension (4%) and diarrhea (4%) were the most common grade 3/4 AEs in I vs <1% in 
C 
Death resulting from AEs: I: 4% vs. C: 3%; 4 deaths (1%) in the pazopanib arm were at-
tributable to study treatment – ischemic stroke, abnormal hepatic function, rectal hemor-
rhage and peritonitis/bowel perforation. 
Commentary Efficacy regarding PFS and response rate was better in treatment nai¨ve patients compared 
to cytokine pre-treated patients. Though, the safety profile between treatment-nai¨ve and 
cytokine pre-treated pts is similar, more pts in the cytokine pre-treated arm (19%) discon-
tinued treatment because of AEs compared to treatment-nai¨ve pts (12%). 
 
Initially, only patients progressing on prior systemic cytokine-based therapy 
were enrolled to the study. After the enrolment of the first 7 patients the 
protocol was amended to also include treatment-naïve patients due to 
emerging evidence on the efficacy of angiogenesis inhibitors and decreased 
use of cytokines in the first-line setting of RCC therapy. Patients were ran-
domly assigned 2:1 to pazopanib vs. placebo. The demographic characteris-
tics were well balanced between the two treatment arms with the majority of 
patients being male (71%) and an average age of 59 years. 
For the primary outcome measure, PFS, pre-defined subgroup-analyses were 
conducted for Memorial Sloan-Kettering Cancer Center (MSKCC) risk cate-
gory, Eastern Cooperative Oncology Group performance status (ECOG PS), 
sex and age. These subgroup-analyses showed that PFS was improved in pa-
tients treated with pazopanib compared to placebo. 
protocol amendment to 
also include treatment-
nai¨ve patients 
subgroup-analyses 
confirm superiority of 
pazopanib over placebo 
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At time of data cut-off, 78% of patients in the intervention arm and 90% of 
patients in the control arm had already discontinued study treatment due to 
several reasons. The most common reasons were disease progression (I: 51%; 
C: 77%), death (I: 4%, C: 6%), adverse events (I: 14%, C: 3%) protocol viola-
tion (I: <1%, C: none), investigator decision (I: 3%, C: <1%), loss to follow-
up, withdrew consent, and other (I: 6%, C: 3%). 
Regardless of previously treated or untreated patients, adverse events oc-
curred more frequently and were more severe in patients treated with pa-
zopanib compared to placebo. 
The most common clinical laboratory abnormalities observed in the pa-
zopanib arm were elevations in the liver enzymes AST and ALT. After dose 
modification, interruption or discontinuation of treatment, recovery in 45 of 
52 patients with ALT elevations could be observed. The other seven patients 
did not have adequate follow-up data to assess recovery. 
Health-related quality of life was assessed by applying three different quality 
of life measure instruments – European Organisation for Research and 
Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30), 
EuroQuol questionnaire (EQ-5D) and visual analogue scale (VAS). Overall 
the completion of questionnaires was high (>90%). No statistical and clini-
cal significant difference in health-related quality of life between placebo 
and pazopanib group was observed at any assessment time point. 
6.2 Efficacy and safety - further studies 
Hutson et al. (2010) [5] conducted a phase II study which was initially 
planned as a randomized discontinuation study: after a 12 week open-label 
phase with daily 800mg pazopanib, patients with stable disease should enter 
a RCT. However, the Independent Data Monitoring Board decided to halt 
the randomization at the first interim analysis (as soon as 60 patients com-
pleted 12 weeks of pazopanib treatment) due to the response rate of 38%. 
Subsequently all patients were treated with pazopanib on an open-label ba-
sis. 
The primary endpoint of this revised protocol was objective response rate 
(RR) and the secondary endpoints were duration of response and PFS as-
sessed by an independent review committee (IRC). The overall study popu-
lation was 225 RCC patients with the histological subtype predominant 
clear-cell. The RR was 35% (95% CI, 28% to 41%) for the overall study 
population (n=225). For the treatment naïve patients (n=155) it was 34% 
(95% CI, 26% to 41%) and for previously treated patients (n=70) RR was 
37% (95% CI, 26% to 49%). The median duration of response was 68 weeks 
(95% CI, 53.7 to not mentioned) and PFS by IRC was 45 weeks (95% CI, 36 
to 59 weeks) for the overall study population. 
Subgroup analyses for PFS showed that ECOG PS and time from diagnosis 
until start of therapy were correlated with prolonged PFS. 
The safety analysis was based on the all-enrolled population. The most 
common treatment emergent adverse events (reported by investigator) were 
diarrhoea (63%), fatigue (46%), hair depigmentation (43%), nausea (42%) 
and hypertension (41%). The most common grade 3 or 4 treatment-related 
adverse events were hypertension (8%), increased ALT (6%), increased AST 
reasons for study 
discontinuation: 
progressive disease, 
death, AEs, etc. 
AEs occurred more 
frequent and more sever 
in pazopanib group 
dose modifications due 
to elevations in liver 
enzymes ALT and AST 
no difference in HRQL 
between study groups 
was observed  
protocol revision due to 
RR after first interim 
analysis 
study outcomes: RR, 
duration of response , 
PFS 
median duration of 
response: 68 weeks 
median PFS: 45 weeks 
treatment-related AEs: 
diarrhoea, fatigue, hair 
depigmentation, nausea 
and hypertension 
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(4%), diarrhoea (4%), and fatigue (4%). 31% of patients had a dose reduc-
tion to 400mg daily due to adverse events. 34 (15%) patients discontinued 
pazopanib due to adverse events. 
7 Estimated costs 
Pazopanib is approved as a once daily administered tablet at a dose of 
800mg for adult patients. In Austria there are two different packages of pa-
zopanib via the producer available: either 30 tablets, each containing 200mg 
pazopanib at a price of € 833 or 30 tablets, each containing 400mg pazopanib 
at a price of € 1,666. Applying these data, one month of treatment with pa-
zopanib would be € 3,331.- [15]. Sternberg et al. 2010 [3] reported a median 
duration of exposure to pazopanib therapy in the pivotal phase III study of 
7.4 months. Multiplying the estimated monthly treatment costs of € 3,300.- 
by 7.4 months, estimated overall treatment costs would be € 24,420.- for the 
treatment of locally advanced and/or metastatic RCC. 
8 Ongoing research 
Currently, there are 4 trials assessing the efficacy and safety of pazopanib in 
different RCC patient groups and in different treatment options registered 
at www.clinicaltrial.gov – one RCT comparing pazopanib to placebo, two 
trials comparing pazopanib and sunitinib and one open-label trial [4]. 
NCT00720941, NCT01064310: These two trials compare the efficacy, safety 
and tolerability of pazopanib and sunitinib head-to-head. The study results 
of these two agents showed similar safety and efficacy profiles when both 
were compared to placebo [5]. One of these two studies is assessing the non-
inferiority of the one agent over the other and the NCT01064310 trial is de-
signed to identify patients’ preferences in the choice of the TKIs for the 
treatment of their disease. 
NCT00334282: This is the pivotal trial assessing the efficacy and safety of 
pazopanib in locally advanced and/or metastatic RCC presented in chapter 
6.1. The VEG105192 trial is still ongoing to assess the secondary endpoint of 
overall survival. 
NCT00387764: Patients in the VEG105192 trial, the pivotal phase III trial 
presented in chapter 6.1 had the option to receive pazopanib in an open-
label study when progressing in placebo. This open-label trial is expected to 
be completed by the end of year 2012. 
Further, plenty of phase I and II trials assessing the safety and efficacy of 
pazopanib in different therapy combinations and therapy lines and different 
indications are registered at www.clinicaltrial.gov. 
one month pazopanib 
monotherapy: 
approximately € 3,300.- 
4 phase III trials 
evaluating the efficacy 
and safety of pazopanib 
in RCC are registered at 
www.clinicaltrial.gov 
sunitinib vs. pazopanib 
patient preference study 
pivotal study still 
ongoing to assess OS 
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9 Commentary 
Sternberg et al. 2010 [3] published data of a phase III trial investigating the 
efficacy of pazopanib for the treatment of RCC, which confirmed the effi-
cacy of pazopanib observed in another phase II trial [5]. In the overall study 
population treatment with pazopanib resulted in a 5 month increase of PFS 
in comparison to placebo, with similar results for overall response rate (RR; 
I 30% vs. C 3%). Subgroup-analyses of PFS and RR in treatment-naïve and 
cytokine pre-treated patients showed that the treatment effect was more 
pronounced in the treatment-naïve cohort. The difference of median PFS 
between pazopanib and placebo was 8.3 months in the treatment-naïve co-
hort and 3.2 months in the cytokine pre-treated cohort. 
The safety and tolerability profile of pazopanib was considered to be accept-
able and clinically manageable, although, grade 3 and 4 AEs, were observed 
in 33% of patients and 14% of patients discontinued therapy because of AEs. 
The most common observed AEs were of grade 1 or 2. The most common 
grade 3 or 4 AEs were hypertension, diarrhoea and elevations in the liver en-
zymes AST and ALT. Elevations in the liver transaminases resulted in dose 
modifications, interruption or discontinuation of treatment. 
Health-related quality of life (HRQL) was assessed with three different in-
struments at pre-defined points in time. At none of these evaluation points, 
statistically or clinically significant difference in HRQL was observed be-
tween placebo and pazopanib group [3]. 
Both, the EMA and the FDA concluded in their benefit-risk assessment that 
the benefits of the pazopanib therapy in locally advanced and/or metastatic 
RCC patients outweigh its risks. The benefit-risk balance is not only found 
to be statistically significant, but is also considered to be clinically relevant 
[2, 6]. 
Whereas FDA granted regular approval, EMA granted conditional market-
ing authorisation of pazopanib for the treatment of RCC. The treatment of 
patients with severe hepatic impairment is explicitly not recommended due 
to the occurrence of hepatic failures including fatalities during treatment 
with pazopanib. Due to elevations in ALT and AST in clinical trials, both 
regulatory authorities, EMA and FDA, emphasized the importance to per-
form regular serum liver tests in order to test the hepatic function and to 
avoid severe hepatic impairment [2, 6, 17].  
Both regulatory agencies requested further efficacy, safety and tolerability 
data of RCC patients treated with pazopanib. On the one hand the market-
ing authorisation holder has to submit mature data on OS of the pivotal 
phase III trial VEG105192 and on the other hand direct comparison data of 
the two agents pazopanib and sunitinib in a currently ongoing phase III 
(COMPARZ trial, NCT00720941 [18]) comparative trial are awaited. 
The reason is, that since 2006 six targeted agents for the treatment of RCC 
have been approved and that up to now there are no direct comparative data 
of these agents available to allow an accurate estimation of the differences 
between the treatment options. The question is how an appropriate choice of 
therapy can be made in clinical practice in the light of the current data 
about the efficacy and safety of pazopanib and the other approved agents. In 
clinical practice adverse event profiles, mode of administration and other 
factors are used for the choice of therapy. Though, applying these factors 
5 months increase in PFS 
RR 30% pazopanib vs. 
3% placebo 
 
treatment effect 
stronger in treatment-
nai¨ve patients 
AEs are clinically 
manageable 
grade 3/4 AEs: 
hypertension, diarrhoea, 
elevations in liver 
enzymes 
benefit-risk balance is 
found to be positive 
pazopanib not suitable 
for pts with severe 
hepatic impairment 
regular liver function 
tests are recommended  
mature OS data and 
direct head-to-head 
comparison data are still 
awaited 
several treatment 
options available and 
lack of comparative data 
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cannot substitute the need to conduct direct head-to-head comparisons to al-
low accurate estimations of the differences between the available treatment 
options [2]. Again, both the FDA and the EMA stated that this head-to-head 
comparative trial has to be designed carefully to allow an accurate estima-
tion of efficacy and safety of these two agents. When compared to placebo, 
pazopanib and sunitinib have a similar efficacy profile - RR 35% vs. 31% 
and median PFS 12 months vs. 11 months for sunitinib and pazopanib, re-
spectively [5]. Recently, Pal et al. 2010 [19] criticised in their paper the 
choice of PFS as the primary endpoint in the COMPARZ trial, stating, that 
if PFS of these two agents is similar, – as it is expected [20] – clinicians will 
still have to face the decision of choosing between two equally efficacious 
agents [19]. 
Another issue the EMA pointed out, is the fact that pazopanib has only been 
assessed in patients with advanced and/or metastatic RCC who are treat-
ment-naïve or cytokine pre-treated [2]. Additionally it has to be mentioned 
that the study populations in the phase II as well as in the phase III trial 
were of the histological subtype clear-cell and predominantly clear-cell (ap-
proximately 60% of all RCC). Therefore, RCC patients other than clear-cell 
or predominantly clear-cell and refractory to other systemic therapy than cy-
tokines should not – due to absence of safety and efficacy data – be treated 
with pazopanib [2]. 
Overall, the efficacy and safety profile of pazopanib is considered positive. 
Though, there are still a couple of questions unanswered – e.g. mature OS 
data of the ongoing pivotal phase III trial and direct comparative data of pa-
zopanib and other approved agents and the efficacy and safety of 2nd-line pa-
zopanib in patients initially treated with other systemic therapy than cyto-
kines. 
Based on the current evidence on the available targeted agents for the first-
line treatment of locally advanced and/or metastatic RCC, it is not possible 
to accurately define superiority in terms of clinical efficacy for one of the 
agents over another. 
 
2nd-line therapy only for 
cytokine pre-treated 
patients available 
direct comparison 
necessary to allow right 
choice of therapy 
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